Glasdegib Absolute Bioavailability Study

Phase 1 Completed 12 enrolled Pfizer

RandomizedCrossoverOpen-labelBasic science

Summary

This study is intended to estimate the absolute bioavailability of Glasdegib by comparison of the pharmacokinetic exposures following administration of an oral, single dose 100 mg tablet vs. an IV infusion of a 50 mg IV dose in the fasted state in a crossover fashion to healthy volunteers.

Timeline

Start: 2017-09-07
Primary completion: 2017-10-06
Completion: 2017-10-30

Publications

Shaik N, Hee B, Liang Y, LaBadie RR. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. Clin Pharmacol Drug Dev. 2019 Oct;8(7):895-902. doi: 10.1002/cpdd.692. Epub 2019 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glasdegib	Small molecule	50 mg	Oral
Subject	Glasdegib	Small molecule	100 mg	Oral

Indications

No indication recorded.